Standardization of Multi-modal Tumor Ablation Therapy System

Inclusion Criteria:

* 1.Adults aged 18 years to 70 years of either gender;
* 2\. Histologically/cytologically confirmed hepatocellular carcinoma or colorectal cancer with liver metastasis, the primary lesion had underwent radical resection and without local recurrent, extrahepatic metastasis;
* 3\. At least one measurable liver metastasis by RECIST criteria. No more than 5 lesions and smaller than 4.0 cm each;
* 4\. Patients' liver function classified as Child-Pugh A or B, total bilirubin \<=3.0 mg/dL, serum creatinine \<= 2.5 mg/dL, White blood cell count \>= 2.0×10\^9/L, Platelets \>= 100×10\^9/L;
* 5\. Performance Status(PS): Eastern cooperative Oncology Group (ECOG) \<= 2, and life expectancy longer than three months;
* 6\. Prior therapy, e.g., chemotherapy, radiation, is allowed provided that more than one month washout time is given, and recover from the previous treatment: according to the Common Terminology Criteria Adverse Events (CTC AE) version 4.0, all side effects (except for hair loss) degrading to 1 level or lower.

Exclusion Criteria:

* 1\. Child-Pugh grade Class C, or tumor invasion into the portal vein;
* 2\. Patient underwent previous cryoablation or other thermal ablation;
* 3\. Patient underwent prior therapy, e.g., chemotherapy, radiation,or other anti-cancer medication no more than 3 weeks;
* 4\. Patients with severe disorders of heart, lung, liver, kidney function or irreversible coagulation disorder;
* 5\. Patients combined with other uncontrolled disease, including but not limited to: hypertension or diabetes, active infection, or mental illness or social condition that may affect the subject's compliance;
* 6\. Pregnant or lactating women.